Keel Point’s GT Biopharma GTBP Stock Holding History

Keel Point’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.2K	Hold	20,768	–	–	﹤0.01%	514
2026 Q1	$8.47K	Buy	+20,768	New	+$11.3K	﹤0.01%	465

Other funds holding GTBP

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

OWA

Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

4WM

49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return

Alongside Austin, Texas $525M AUM

Keel Point's GTBP Position: Q2 2026 in Review

Keel Point held its GT Biopharma (GTBP) position steady in Q2 2026 at 20,768 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #514.

Keel Point first reported a position in GTBP in Q1 2026 and has held it in 2 quarters since. 59 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

Keel Point held 20,768 shares of GT Biopharma worth $10.2K as of Q2 2026.
Keel Point left its GT Biopharma share count unchanged in Q2 2026.
GT Biopharma made up ﹤0.01% of Keel Point's portfolio in Q2 2026, its #514 holding.
Keel Point first reported a position in GT Biopharma in Q1 2026 and has held it in 2 quarters since.
59 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Keel Point's 13F filing for Q2 2026, filed 14 Aug 2026.